Cantor Fitzgerald Estimates STOK FY2026 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share estimates for Stoke Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings of ($2.51) per share for the year. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million.

STOK has been the topic of a number of other research reports. Chardan Capital reiterated a "buy" rating and set a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, April 9th. Finally, HC Wainwright lowered their target price on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $23.20.

Stoke Therapeutics Stock Down 2.5%

Stoke Therapeutics stock traded down $0.29 during trading hours on Tuesday, hitting $11.53. The stock had a trading volume of 478,274 shares, compared to its average volume of 699,976. The company has a 50-day moving average of $9.30 and a two-hundred day moving average of $9.66. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $17.34. The company has a market cap of $629.50 million, a PE ratio of -5.49 and a beta of 1.09.

Insider Transactions at Stoke Therapeutics

In other news, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Barry Ticho sold 6,471 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $10.03, for a total value of $64,904.13. Following the sale, the insider now owns 25,782 shares in the company, valued at approximately $258,593.46. This trade represents a 20.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,748 shares of company stock valued at $225,687. 9.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC increased its stake in shares of Stoke Therapeutics by 1,842.0% in the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock valued at $36,000 after buying an additional 5,084 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in Stoke Therapeutics during the 4th quarter worth about $63,000. Teacher Retirement System of Texas bought a new stake in Stoke Therapeutics during the 4th quarter worth about $113,000. AlphaQuest LLC acquired a new stake in Stoke Therapeutics in the 1st quarter valued at about $72,000. Finally, US Bancorp DE raised its stake in shares of Stoke Therapeutics by 9,743.9% in the first quarter. US Bancorp DE now owns 11,222 shares of the company's stock worth $75,000 after acquiring an additional 11,108 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.